![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/JAGSNPHARM.png)
Share the post "Jagsonpal Pharmaceuticals ‘s Q3 2024-25 Latest News: Revenue Up by 56.72% Year-on-Year"
Highlights
🔹 The presented financial data is Standalone to provide a comprehensive overview of the company performance. 🔹 Sales over the Year and quarter: The company experienced a substantial growth of 56.72 % in the past year, decrease in net sales/revenue by -0.89 %. 🔹 Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 911.74 %. Marginal increase in other income during this quarter, up by 1442.08%. 🔹 Profit over the Year and quarter: Significant improvement in profitability for Jagsonpal Pharmaceuticals Limited. Notable increase of 707.22 % in net profit Year to Year, Jagsonpal Pharmaceuticals Limited’s profitability increased by 179.17 % in this quarter. 🔹 EPS over the Year and quarter: EPS increased by 703.39 % Year to Year. EPS increased by 175.58 % in previous quarter. Positive impact on shareholders.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 47.234 Cr | Rs. 74.692 Cr | Rs. 74.025 Cr | -0.89 % | + 56.72 % |
| Expenses | Rs. 43.83 Cr | Rs. 58.41 Cr | Rs. 58.19 Cr | -0.38 % | + 32.76 % |
| Operating Profit | Rs. 3.4 Cr | Rs. 16.28 Cr | Rs. 15.84 Cr | -2.7 % | + 365.88 % |
| OPM % | 7.2 % | 21.8 % | 21.4 % | -0.4 % | + 14.2 % |
| Other Income | Rs. 2.521 Cr | Rs. 1.654 Cr | Rs. 25.506 Cr | + 1442.08 % | + 911.74 % |
| Interest | Rs. 0.23 Cr | Rs. 0.23 Cr | Rs. 0.26 Cr | + 13.04 % | + 13.04 % |
| Depreciation | Rs. 0.41 Cr | Rs. 2.34 Cr | Rs. 2.41 Cr | + 2.99 % | + 487.8 % |
| Profit before tax | Rs. 5.28 Cr | Rs. 15.36 Cr | Rs. 38.68 Cr | + 151.82 % | + 632.58 % |
| Tax % | 24.93 % | 25.44 % | 17.28 % | -8.16 % | -7.65 % |
| Net Profit | Rs. 3.96 Cr | Rs. 11.46 Cr | Rs. 31.99 Cr | + 179.14 % | + 707.83 % |
| EPS in Rs | Rs. 0.59 | Rs. 1.7 | Rs. 4.74 | + 178.82 % | + 703.39 % |
Today, we’re looking at Jagsonpal Pharmaceuticals Limited’s financial performance for the Q3(Dec 2024-25).Starting with the top line, the company reported a robust year-over-year sales growth of 56.72 %. However, it did see a marginal slip of -0.89 % from the previous quarter. Expenses decreased slightly by -0.38 % quarter-on-quarter, aligning with the annual rise of 32.76 %. Operating profit, while up 365.88 % compared to last year, faced a quarter-on-quarter dip of -2.7 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 14.2 %, but a shrinkage of -0.4 % sequentially. Other income rose by 1442.08 % compared to the last quarter, despite an annual growth of 911.74 %. Interest expenses surged remarkably by 13.04 % from the previous quarter, yet the year-over-year increase remains at a moderate 13.04 %. Depreciation costs climbed by 2.99 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 487.8 %. Profit before tax grew annually by 632.58 % but saw an increase from the preceding quarter by 151.82 %.
Tax expenses as a percentage of profits decreased slightly by -7.65 % compared to last year, with a more notable quarter-on-quarter decrease of -8.16 %. Net profit rose by 707.83 % year-on-year but experienced a 179.14 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 703.39 % but a quarterly rise of 178.82 %. In summary, Jagsonpal Pharmaceuticals Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 47.234 Cr | Rs. 74.692 Cr | Rs. 74.025 Cr | -0.89 % | + 56.72 % |
| Expenses | Rs. 43.83 Cr | Rs. 58.41 Cr | Rs. 58.19 Cr | -0.38 % | + 32.76 % |
| Operating Profit | Rs. 3.4 Cr | Rs. 16.28 Cr | Rs. 15.84 Cr | -2.7 % | + 365.88 % |
| Net Profit | Rs. 3.96 Cr | Rs. 11.46 Cr | Rs. 31.99 Cr | + 179.14 % | + 707.83 % |
| EPS in Rs | Rs. 0.59 | Rs. 1.7 | Rs. 4.74 | + 178.82 % | + 703.39 % |
In reviewing Jagsonpal Pharmaceuticals Limited’s 2024-25(Q3) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 56.72 % year-on-year growth, although there was a slight dip of -0.89 % from the previous quarter. Expenses rose by 32.76 % compared to the previous year, with a decrease of -0.38 % quarter-on-quarter. Operating Profit surged by 365.88 % annually, and saw a -2.7 % decrease from the last quarter.
Net Profit showed yearly increase of 707.83 %, and experienced a 179.14 % increase from the previous quarter. Earnings Per Share (EPS) rose by 703.39 % annually, however rose by 178.82 % compared to the last quarter. In essence, while Jagsonpal Pharmaceuticals Limited exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.
![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/EICHERMOT.png)